PMID 18787098
Toward a theory of childhood learning disorders, hyperactivity, and aggression
Reagents Primary antibodies to beta actin, S100beta and Iba-1 were purchased from Abcam (Cambridge, MA)
Important Considerations for Combining NAD+ and AOD9604 Despite the theoretical appeal, several crucial points must be considered when exploring the combination of NAD+ and AOD9604: Lack of Direct Combined Research: The most significant caveat is the current lack of extensive human clinical trials specifically investigating the combined effects of NAD+ precursors and AOD9604
How FDA evaluates substances for the 503A Bulks List Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA evaluates nominated bulk drug substances using several statutory and regulatory considerations, including the clinical need for compounding, available safety information, historical use in pharmacy compounding, and the potential risks associated with permitting or denying their use in compounded medications